According to Insmed Incorporated both the US and European patent offices are granting new patents related to the company’s Arikace liposomal amikacin for inhalation to treat Pseudomonas aeruginosa lung infections in cystic fibrosis patients and for non-tuberculous mycobacteria (NTM) lung infections.
The company says that the US Patent and Trademark Office (USPTO) will grant it a patent titled “Lipid-based compositions of anti-infectives for treating pulmonary infections and methods of use thereof” (US application no. 13/666,420), which will provide exclusivity through at least December 5, 2026. The USPTO has previously issued composition of matter patents covering Insmed’s inhaled liposomal amikacin in May 2010 and in July 2012.
In addition, the company said, the European Patent Office will grant a patent titled “Sustained release of anti-infectives” (EU application no. 03816990) with exclusivity at least through October 29, 2023. Insmed was granted EU patent No. 1909759 for Arikace earlier this year.
Insmed President and CEO Will Lewis commented, “These new patent allowances are a credit to our technology development team and demonstrate the inventiveness and utility of our approach to treating serious and oftentimes life-threatening lung diseases. As we move toward potential marketing approval and commercialization of Arikace to treat Pseudomonas aeruginosa in CF patients in Europe and Canada, and continue the clinical development of our liposomal amikacin for inhalation to treat NTM in the US, these new patent allowances provide additional protection for this valuable asset. We are pursuing a broad intellectual property strategy that provides the foundation to achieve our global clinical and commercial objectives and protects shareholder value.”
Read the Insmed press release.
